Eric Dube, CEO of Travere Therapeutics, leads the company with extensive experience in the pharmaceutical industry. After earning his B.S. from Santa Clara University and a Ph.D. from Cornell University, he took the helm at Travere on January 4, 2019....

Eric Dube, CEO of Travere Therapeutics, leads the company with extensive experience in the pharmaceutical industry. After earning his B.S. from Santa Clara University and a Ph.D. from Cornell University, he took the helm at Travere on January 4, 2019. Before joining, he was the head of North America at ViiV Healthcare and held various senior roles at GlaxoSmithKline, focusing on respiratory and oncology drugs. During his time as CEO, Dube has guided Travere through challenges like COVID-19 while pushing for corporate goals related to drug development and patient outreach. Under his watch, the company's equity awards indicate a focus on long-term growth, with substantial stock options granted to him, aligning his success with that of the company. He has been proactive in enhancing shareholder value, which shows in his stock transactions, pulling multi-million dollar amounts throughout 2021. This reflects a deep commitment to not just lead the company but also personally invest in its future. Dube’s leadership mixes academic knowledge with practical experience, aiming to create effective therapies for patients in need.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Travere Therapeutics, Inc. CEOs

T

Eric Dube

CEO of Travere Therapeutics, Inc.

Education

Ph.D. from Cornell University

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

November 20, 1972 - 52 years ago

CEO of Travere Therapeutics, Inc. for

6 years 6 months (Jan 2019 - Present)

Previous Experience

Head, North America of Viiv Healthcare Limited

Rivals

Competitors/colleagues of Eric Dube

Holdings

See how much did Eric Dube make over time.

Eric Dube's holdings in Travere Therapeutics have seen impressive activity. In 2021, he executed stock transactions totaling between $2 million to $4 million almost every month, culminating in his most significant transaction at $4.58 million in February 2021. This early...

Eric Dube's holdings in Travere Therapeutics have seen impressive activity. In 2021, he executed stock transactions totaling between $2 million to $4 million almost every month, culminating in his most significant transaction at $4.58 million in February 2021. This early momentum demonstrated his confidence in the company's potential. His wealth mainly comes from his holdings in Travere, indicating a strong personal investment in the company’s future success. As of the most recent reports, Dube has accumulated a substantial number of unexercised stock options and RSUs, reflecting both his commitment and belief in Travere's growth trajectory. The market's performance and his trading patterns suggest he closely tracks the company's development progress, demonstrating a real alignment with investor interests.

Loading...

Total Stock Sold

$4.60M

TVTX

$4.60M

225,530 TVTX shares

What if they kept their stock?

If Eric Dube didn't sell their stock, today they would have:
Extra TVTX225,530 shares worth $5.56M.
This is 20.93% and $962.40K more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Eric Dube.

TVTX

$273.46K

TVTX at $24.04/share

Feb 11, 2025

Sale

TVTX

$1.02M

TVTX at $20.21/share

Jan 31, 2025

Sale

TVTX

130,000 shares

TVTX

Jan 31, 2025

Received

TVTX

$208.92K

TVTX at $19.46/share

Jan 22, 2025

Sale

TVTX

$243.36K

TVTX at $11.52/share

Sep 5, 2024

Sale

TVTX

32,500 shares

TVTX

Sep 5, 2024

Received

TVTX

$166.29K

TVTX at $8.70/share

Jan 31, 2024

Sale

TVTX

135,000 shares

TVTX

Jan 31, 2024

Received

TVTX

$70.54K

TVTX at $8.96/share

Jan 23, 2024

Sale

TVTX

$65.53K

TVTX at $14.71/share

Aug 31, 2023

Sale

Compensation History

See how much did Eric Dube make over time.

Eric Dube’s compensation reflects his pivotal role at Travere Therapeutics. For 2021, his total compensation reached about $1.27 million, which included a base salary of $710,000, a bonus based on company performance goals, and a significant portion in long-term stock options. His bonus target was set at 65% of his salary, rewarding him for achieving the corporate goals set for that year. Dube’s focus has been on aligning his compensation with the company's long-term growth, which is evident in the substantial stock options granted to him from the start of his tenure. In previous years, such as 2020 and 2019, his compensation also showed a strong performance link, showcasing a consistent pay structure designed to motivate and retain high-level leadership in a competitive industry.

Year

2021

Total Compensation

$1.28M

Salary

$710.00K

Board Justification

The compensation philosophy aims to attract, retain, and motivate executives through competitive compensation packages that align with company performance and peer benchmarking.

Bonus

$553.80K

Board Justification

The target bonus percentage was set at 65% of base salary for the Company’s CEO and was based on the achievement of corporate performance goals, with actual performance resulting in a payout of 78%.

Other

$11.86K

Board Justification

Other compensation includes health insurance premiums and 401(k) matching contributions.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was reported as vested in 2021 for Eric Dube.

Performance Metrics

The performance metrics for determining the CEO's compensation included corporate performance goals related to pipeline advancement, patient service increase, and maintaining a robust organizational culture.

Other Travere Therapeutics, Inc. CEOs

Here are other CEOs of Travere Therapeutics, Inc.

Stephen Aselage

Ex-CEO of Travere Therapeutics, Inc.

September 2014 - January 2019